Search

Archie N Tse

from Flushing, NY
Age ~58
Get Report
Also known as:
Archie Ngai-Chiu Tse, Archie Ngai Chiu Tse, Archie Ngai Tse, Tse Archie Ngai-Chiu
Related to:
Yam M Tse
Connected to:
Adam Y Tse, 30Alison Y Tse, 67Alva W Tse, 52Anthony S Tse, 51Belinda Y Tse, 43Calista S Tse, 57Candy S Tse, 63Carlos Tse, 65Cherie M Tse, 53Chun K Tse, 73

Archie Tse Phones & Addresses

  • Flushing, NY
  • Long Island City, NY
  • Alhambra, CA
  • New York, NY
  • Richmond, VA

Work

Company: Memorial Sloan - Kettering Cancer Center Address: 1275 York Avenue, New York, NY 10065

Education

School / High School: Usc Med Center

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Internal Medicine, 2000

Specialities

Oncology • Medical Oncology

Professional Records

Medicine Doctors

Archie Tse Photo 1

Dr. Archie N Tse, New York NY - MD (Doctor of Medicine)

View page
Specialties:
Oncology
Medical Oncology
Address:
1275 York Ave, New York, NY 10065
(646) 227-3813 (Phone)
Certifications:
Internal Medicine, 2000
Medical Oncology, 2003
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1275 York Ave, New York, NY 10065

Memorial Sloan - Kettering Cancer Center
1275 York Avenue, New York, NY 10065
Education:
Medical School
Usc Med Center
Medical School
UCLA Med Center
Graduated: 2000
Medical School
Meml Sloan Kettering Canc Center
Graduated: 2000
Archie Tse Photo 2

Archie Ngai-Chiu Tse, New York NY

View page
Specialties:
General Practice
Internal Medicine
Hematology & Oncology
Medical Oncology
Work:
Memorial Solid Tumor Group
1275 York Ave, New York, NY 10065
Education:
University of Southern California(1997)

Publications

Us Patents

Methods For Treating Cancer With Anti Pd-1 Antibodies And Anti Ctla4 Antibodies

View page
US Patent:
20210047409, Feb 18, 2021
Filed:
Feb 8, 2019
Appl. No.:
16/966988
Inventors:
Mallika LALA - Rahway NJ, US
Lokesh JAIN - Rahway NJ, US
Mengyao LI - Springfield NJ, US
Rachel Allison ALTURA - Rahway NJ, US
Archie Ngai-chiu TSE - Long Island City NY, US
- Rahway NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07K 16/28
A61K 39/395
A61P 35/00
Abstract:
The present invention relates to methods for treating cancer in a patient comprising administering an anti-PD-1 antibody or antigen binding fragment thereof in specific amounts to the patient about every six weeks, in combination with administering an anti-CTLA4 antibody to the patient about every six weeks. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and a dosage of an anti-CTLA4 antibody or antigen-binding fragment thereof, and uses thereof for treating cancer.

Benzo[B]Thiophene Sting Agonists For Cancer Treatment

View page
US Patent:
20200330427, Oct 22, 2020
Filed:
Jul 30, 2018
Appl. No.:
16/635074
Inventors:
- Rahway NJ, US
Jared N. CUMMING - Winchester MA, US
Johnny E. KOPINJA - Newton MA, US
Samanthi A. PERERA - Lexington MA, US
Benjamin Wesley TROTTER - Medfield MA, US
Archie Ngai-Chiu TSE - Long Island City NY, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/381
A61P 35/00
A61P 35/04
A61K 9/00
Abstract:
Therapies comprising administering at least one benzo[b]thiophene compound that activates the Stimulator of Interferon Genes (STING) pathway, and the use of such therapies in the treatment of cell-proliferation disorders such as cancer, are disclosed herein.

Cyclic Dinucleotide Sting Agonists For Cancer Treatment

View page
US Patent:
20200113924, Apr 16, 2020
Filed:
Dec 15, 2017
Appl. No.:
16/472043
Inventors:
- Rahway NJ, US
Jared N. Cumming - Winchester MA, US
Lauren M. Flateland - Roslindale MA, US
Johnny E. Kopinja - Boston MA, US
Yanhong Ma - Newton MA, US
Samanthi A. Perera - Lexington MA, US
Benjamin Wesley Trotter - Medfield MA, US
Archie Ngai-Chiu Tse - Long Island City NY, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/7084
A61P 35/00
Abstract:
Therapies comprising administering at least one cyclic dinucleotide compound that activates the Stimulator of Interferon Genes (STING) pathway, and the use of such therapies in the treatment of cell-proliferation disorders such as cancer, are disclosed herein.

Combinations Of Pd-1 Antagonists And Cyclic Dinucleotide Sting Agonists For Cancer Treatment

View page
US Patent:
20190328762, Oct 31, 2019
Filed:
Dec 15, 2017
Appl. No.:
16/472025
Inventors:
- Rahway NJ, US
Jared N Cumming - Winchester MA, US
Johnny E Kopinja - Boston MA, US
Yanhong Ma - Newton MA, US
Samanthi A Perera - Lexington MA, US
Benjamin Wesley Trotter - Medfield MA, US
Archie Ngai-Chiu Tse - Long Island City NY, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/7084
A61P 35/00
A61K 39/395
Abstract:
Therapeutic combinations that comprise at least one antagonist of the Programmed Death 1 receptor (PD-1) and at least one cyclic dinucleotide compound that activates the Stimulator of Interferon Genes (STING) pathway are disclosed herein. Also disclosed is the use of such therapeutic combinations for the treatment of cancers.
Control profile
Archie N Tse from Flushing, NY, age ~58 Get Report